Bayer is dropping $2.2 billion on its first-ever pharma manufacturing campus in North America, picking New Albany, Ohio, as the site for a massive bet on domestic drug production. It's part of a reshoring tidal wave that's rewriting the rules of where medicine gets made.
For more than a century, Bayer has sold pills in America without ever building a major pharma plant here. That's about to change in a very expensive way.
The German giant just announced a $2.2 billion investment in a brand-new pharmaceutical manufacturing campus in New Albany, Ohio. It's the company's first greenfield pharma production facility in North America, and it's one of the largest single-site pharma investments the industry has seen this year. The first module is expected to come online in 2031, with a second following in 2034.
Six hundred permanent jobs. Fifteen hundred construction jobs. Two hundred acres of Ohio farmland about to become one of the most advanced drug factories on the continent.
So why now?
The Factory That Tariffs Built
Let's rewind a bit. Bayer has operated in the U.S. for decades: labs in Cambridge, offices in New Jersey, a consumer health plant in Pennsylvania that's been running for over 75 years. But all of that was inherited through acquisitions, joint ventures, and decades of corporate reshuffling. The company never sat down and said, "Let's build a state-of-the-art pharma manufacturing campus from scratch in America."
Until the economics forced its hand.
The reshoring wave sweeping U.S. pharma right now is unlike anything the industry has seen. Tariff threats, supply chain anxiety, and federal pressure to bring drug production stateside have turned "Made in America" from a slogan into a business strategy. About 88% of active pharmaceutical ingredient (API) manufacturing for the U.S. market still happens overseas. Washington wants that number to shrink, and companies are listening.
Bayer isn't alone in opening its wallet. Merck has pledged over $70 billion in U.S. expansion. Johnson & Johnson committed $55 billion. Roche put up $50 billion. Eli Lilly carved out $27 billion. That's not a trend; it's a tectonic shift.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Why Ohio, and Why This Design?
New Albany, Ohio, might not scream "pharma powerhouse," but it's quietly becoming one. The site sits in the New Albany International Business Park, and the state is building the Ohio Life Science Training Center nearby, scheduled to open in summer 2027. JobsOhio is investing up to $30 million in workforce development for the region, with another $8 million coming from the city, the state, and a local development company.
Bayer is also pursuing an Ohio Job Creation Tax Credit and additional state incentives, though final terms haven't been made public yet.
The plant itself is designed to be flexible and modular, which is the pharma equivalent of building with Legos instead of concrete. Rather than a single massive facility locked into producing one drug, the campus will combine drug substance manufacturing (making the active ingredient) and drug product manufacturing (turning it into the pill or injection you actually use). That modular approach lets Bayer swap production lines as its portfolio evolves, which matters a lot when your pipeline is changing every few years.
Bayer says the site will lean heavily on digital and automation technologies, and it will initially support three therapeutic areas: oncology, cardiovascular, and renal care.
The Drugs That Could Call Ohio Home
Bayer hasn't officially named which products will roll off the Ohio lines, but the shortlist practically writes itself.
Nubeqa (darolutamide), a prostate cancer drug, is one of Bayer's biggest growth engines right now. Kerendia (finerenone), which treats chronic kidney disease in patients with type 2 diabetes, is expanding into new indications. And asundexian, a next-generation blood thinner in late-stage trials, could be Bayer's most important pipeline asset; bringing its manufacturing closer to the U.S. market would make strategic sense.
There's also Lynkuet (elinzanetant), a menopause treatment that's a near-term commercial priority, and Eylea 8 mg, the high-dose version of Bayer's blockbuster eye drug. If the Ohio campus lives up to its flexible design, it could eventually produce several of these products under one roof.
Think of it like a restaurant kitchen that can switch from Italian to Japanese to Mexican depending on what customers are ordering. The infrastructure stays; the recipes change.
Playing the Long Game
Here's what makes this investment interesting from a Wall Street perspective: it won't move the needle anytime soon. The first module doesn't go live for five years. Full drug product capacity won't arrive until 2034. That's an eight-year runway before the campus is fully operational.
Analysts are treating the project less as an earnings catalyst and more as a platform investment. Bayer is essentially pre-positioning itself for a future where having U.S.-based manufacturing isn't just nice to have; it's table stakes. The company says it has already spent more than $7 billion on U.S. pharma R&D and manufacturing over the past five years. Ohio is the next chapter of that story.
The strategic logic is sound. If tariff pressure continues (and there's no sign it's letting up), companies that manufacture domestically will have a cost advantage over those shipping finished drugs from Europe or Asia. If supply chain disruptions hit again (and they will), having a major facility on American soil provides a buffer that no amount of inventory stockpiling can match.
The Bigger Picture
Bayer's Ohio bet is one piece of a much larger puzzle. A 2025 analysis of global contract manufacturing investment found that 74% of all disclosed capital flowed to the United States, totaling $18.48 billion out of $24.86 billion. The U.S. isn't just attracting pharma investment; it's hoovering it up like a Dyson on overdrive.
Federal policy is helping, too. A 2025 executive order directed the FDA and EPA to streamline permitting and inspections for new domestic pharma sites. The FDA's PreCheck program aims to simplify the review process for facilities built on U.S. soil. The message from Washington is clear: build here, and we'll make the paperwork easier.
But reshoring has limits. New pharma plants can cost up to $2 billion (Bayer's exceeds that) and take five to ten years to become operational. Even with all this investment, the U.S. still depends on overseas suppliers for the vast majority of its raw pharmaceutical ingredients. Building the final factory is only half the battle; the upstream chemistry still happens somewhere else.
For Bayer, though, the Ohio project represents something bigger than manufacturing capacity. It's a signal that the company sees its future in America, and it's willing to write a $2.2 billion check to prove it. Construction could begin as early as mid-2027.
The aspirin company is betting big on American concrete. Now we wait to see what comes off the line.
4 min read
Foghorn Blew Through $300M of Lilly's Cash and Has Nothing to Show for It
Foghorn Therapeutics axed 40% of its workforce after its Eli Lilly-partnered cancer drug flopped in Phase 1. The $1.6 billion collaboration is over, the stock is at $2, and the wreckage tells a cautionary tale about one of oncology's trickiest frontiers.
